Muhammad Helmi Nadri, Wan Mohd Nuzul Hakimi Wan Salleh
Muhammad Helmi Nadri1*, Wan Mohd Nuzul Hakimi Wan Salleh2
1Innovation Centre in Agritechnology (ICA), Universiti Teknologi Malaysia, 84600 Pagoh, Johor, Malaysia.
2Department of Chemistry, Faculty of Science and Mathematics, Universiti Pendidikan Sultan Idris (UPSI), 35900 Tanjung Malim, Perak, Malaysia.
Volume - 13,
Issue - 5,
Year - 2020
The group X secreted phospholipase A2 (sPLA2-X) and cyclooxygenase-2 (COX-2) are enzymes involved in biosynthesis of prostaglandins, a potent mediator of inflammation. The sPLA2-X hydrolysed membrane phospholipids to arachidonic acid and further converted into prostaglandins by COX-2. Previous studies showed that naturally occurring phytochemicals reduced prostaglandins level in cell culture and animal models. In the present study, we investigated molecular interaction between ten phytochemicals from Piper species, with sPLA2-X and COX-2 using in silico molecular docking approaches for potential anti-inflammatory properties. The selected phytochemicals were subjected to docking simulation using Autodock 4.2 software. Docking results were compared with reference drugs including indomethacin, celecoxib and varespladib. The result identified cubebin as potential dual inhibitor of sPLA2-X and COX-2. This compound makes contact with protein target by forming hydrogen bonds and hydrophobic interactions. Cubebin is also predicted to have a lower COX-2 binding energy than indomethacin and celecoxib. Interaction of cubebin with sPLA2-X and COX-2 amino acids indicates the potential as dual enzyme inhibition activities.
Cite this article:
Muhammad Helmi Nadri, Wan Mohd Nuzul Hakimi Wan Salleh. Molecular Docking Studies of Phytochemicals from Piper Species as Potential Dual Inhibitor of Group X Secreted Phospholipase A2 (SPLA2-X) and Cyclooxygenase-2 (COX-2). Research J. Pharm. and Tech 2020; 13(5): 2181-2186. doi: 10.5958/0974-360X.2020.00392.3
Muhammad Helmi Nadri, Wan Mohd Nuzul Hakimi Wan Salleh. Molecular Docking Studies of Phytochemicals from Piper Species as Potential Dual Inhibitor of Group X Secreted Phospholipase A2 (SPLA2-X) and Cyclooxygenase-2 (COX-2). Research J. Pharm. and Tech 2020; 13(5): 2181-2186. doi: 10.5958/0974-360X.2020.00392.3 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-5-22
1. Henderson WR et al. Blockade of human group X secreted phospholipase A2 (GX-sPLA2)-induced airway inflammation and hyperresponsiveness in a mouse asthma model by a selective GX-sPLA2 inhibitor. Journal of Biological Chemistry. 2011; 286(32): 28049-28055.
2. Smart BP et al. The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding. Journal of Medicinal Chemistry. 2006; 49(10): 2858-2860.
3. Bezzine S et al. Exogenously added human group X secreted phospholipase A2 but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells. Journal of Biological Chemistry. 2000; 275(5): 3179-3191.
4. Henderson WR Jr et al. Importance of group X–secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model. Journal of Experimental Medicine. 2007; 204(4): 865-877.
5. Fujioka D et al. Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2–deficient mice. Circulation. 2008; 117(23): 2977-2985.
6. Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. New England Journal of Medicine. 1979; 1142-1147
7. Norregaard R. et al. Physiology and pathophysiology of cyclooxygenase-2 and prostaglandin E2 in the kidney. Kidney Research and Clinical Practice. 2015; 34(4): 194-200.
8. Vane JR et al. Cyclooxygenases 1 and 2. Annual Review of Pharmacology and Toxicology. 1998; 38(1): 97-120.
9. Bishop-Bailey D et al. COX-2 in cardiovascular disease. Arteriosclerosis, Thrombosis and Vascular Biology. 2006; 26: 956-958.
10. Stemme V et al. Expression of cyclooxygenase-2 in human atherosclerotic carotid arteries. European Journal of Vascular and Endovascular Surgery.2000; 20(2): 146-152.
11. Chenevard R et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003: 107(3): 405-409.
12. Korkina LG. Phenylpropanoids as naturally occurring antioxidants: from plant defense to human health. Cellular and Molecular Biology. 2007; 53(1): 15-25.
13. Thai O.B., Essential oils of six Piper species. Master Thesis. 2007. Universiti Teknologi Malaysia.
14. Rajudin E. Phytochemicals and biological activities of selected Piper species. PhD Thesis. 2009. Universiti Teknologi Malaysia.
15. Fabarani N.P., Phytochemicals and antibacterial activity of Piper retrofractum Vahl. and Piper arborescens Roxb. Master Thesis. 2012. Universiti Teknologi Malaysia.
16. Salleh W.M.N.H.W., Essential oils, phytochemicals, and biological activities of Piper caninum C.DC. and Piper officinarum C.DC. Master Thesis. 2012. Universiti Teknologi Malaysia.
17. Salleh WMNHW et al. Antioxidant and anti-tyrosinase activities from Piper officinarum C.DC (Piperaceae). Journal of Applied Pharmaceutical Sciences. 2014; 4(5): 87-91.
18. Hashim N.A., Phytochemicals and bioactivities of Piper maingayi HK.F., Piper magnibaccum C.DC., and Piper caninum C.D.C. PhD Thesis. 2018. Universiti Teknologi Malaysia.
19. Kurumbail RG et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996; 385(6616): 555.
20. Chen H et al. Discovery of a novel pyrazole series of group X secreted phospholipase A2 inhibitor (sPLA2-X) via fragment based virtual screening. 2014; Bioorganic & Medicinal Chemistry Letter. 2014; 24(22): 5251-5255.
21. Rizvi SM et al. A simple click by click protocol to perform docking: AutoDock 4.2 made easy for non-bioinformaticians. Excli Journal. 2013; 12: 831-857.
22. Laskowski RA, Swindells MB. LigPlot+: multiple ligand–protein interaction diagrams for drug discovery, Journal of Chemical Information and Modeling. 2011; 51(10): 2778-2786.
23. Zadorozhnii PV et al. In Silico Prediction and Molecular Docking Studies od N-Amidoalkylated Derivatives of 1,3,4-Oxadiazole as COX-1 and COX-2 Potential Inhibitors. Research Journal of Pharmacy and Technology. 2017; 10(11): 3957-3963.
24. Sudha R et al. In Silico Analysis of Various Benzilate Derivatives Towards Cyclooxygenase 2 Enzyme. 2019; 12(1):347-350.
25. Blobaum, A. L., and Marnett, L. J. Structural and functional basis of cyclooxygenase inhibition. Journal of medicinal chemistry. 2007; 50(7), 1425-1441.
26. Blobaum, A.L, Shu X, Scott W.R, Kelsey C.D, Surajit B, Shalley N.K, William R.B, Kebreab G, and Lawrence J. Action at a distance: mutations of peripheral residues transform rapid reversible inhibitors to slow, tight binders of cyclooxygenase-2. Journal of Biological Chemistry. 2015; 290(20): 12793-12803.
27. Alam, M. J., Alam, O., Khan, S. A., Naim, M. J., Islamuddin, M., & Deora, G. S. Synthesis, anti-inflammatory, analgesic, COX1/2-inhibitory activity, and molecular docking studies of hybrid pyrazole analogues. Drug Design, Development and Therapy. 2016; 10, 3529-3543.
28. Orlando BJ and Malkowski MG. Crystal structure of rofecoxib bound to human cyclooxygenase-2. Acta Crystallographica Section F, Structural Biology Communication. 2016; 72(10): 772-776.
29. Knights KM et al. Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Review of Clinical Pharmacology. 2010; 3(6): 769-776.
30. Bastos JK et al. Anti-inflammatory activity of cubebin, a lignan from the leaves of Zanthoxyllum naranjillo Griseb, Journal of Ethnopharmacology. 2001; 75: 279-282
31. Son D et al. Piperine inhibits the activities of platelet cytosolic phospholipase A2 and thromboxane A2 synthase without affecting cyclooxygenase-1 activity: different mechanisms of action are involved in the inhibition of platelet aggregation and macrophage inflammatory response. Nutrients. 2014; 6(8): 3336-3352.
32. Meyer MC et al. Phospholipase A2 inhibitors as potential anti-inflammatory agents. Current Pharmaceutical Design. 2005; 11(10): 1301-1312.
33. Giordanetto F et al. Discovery of AZD2716: A novel secreted phospholipase A2 (sPLA2) inhibitor for the treatment of coronary artery disease. ACS Medicinal Chemistry Letter. 2016; 7(10): 884-889